ESPR: Esperion Therapeutics Inc. Stocks News on November 8, 2024

ESPR

GuruFocus.com

11 hours ago

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

ESPR

Zacks

a day ago

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

ESPR

Zacks

a day ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

ESPR

Associated Press Finance

a day ago

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

ESPR

GlobeNewswire

a day ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ESPR

GlobeNewswire

4 days ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ESPR

Zacks

8 days ago

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

ESPR

GlobeNewswire

8 days ago

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7

ESPR

GlobeNewswire

15 days ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

ESPR

GuruFocus.com

22 days ago

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

ESPR

Insider Monkey

a month ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

ESPR

GlobeNewswire

a month ago

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ESPR

GlobeNewswire

a month ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ESPR

Zacks

2 months ago

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

ESPR

GlobeNewswire

2 months ago

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

ESPR

GlobeNewswire

2 months ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ESPR

GlobeNewswire

2 months ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ESPR

Thomson Reuters StreetEvents

3 months ago

Q2 2024 Esperion Therapeutics Inc Earnings Call

ESPR

MT Newswires

3 months ago

Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

ESPR

Zacks

3 months ago

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

ESPR

Zacks

3 months ago

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

ESPR

Associated Press Finance

3 months ago

Esperion Therapeutics: Q2 Earnings Snapshot

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

ESPR

GlobeNewswire

3 months ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

ESPR

Zacks

3 months ago

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR

GlobeNewswire

3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR

Zacks

3 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion to Report Second Quarter 2024 Financial Results on August 12

ESPR

GlobeNewswire

3 months ago

Esperion to Report Second Quarter 2024 Financial Results on August 12

Esperion to Participate in Upcoming BTIG Biotech Conference

ESPR

GlobeNewswire

3 months ago

Esperion to Participate in Upcoming BTIG Biotech Conference

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

ESPR

Zacks

4 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

ESPR

GlobeNewswire

4 months ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

ESPR

MT Newswires

4 months ago

Esperion Therapeutics Enters $304.7 Million Royalty Purchase Agreement with OMERS; Shares Rise

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

ESPR

BioPharma Dive

4 months ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

ESPR

GlobeNewswire

4 months ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

ESPR

Zacks

5 months ago

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

ESPR

GOBankingRates

5 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

ESPR

AFP

5 months ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

ESPR

AFP

5 months ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally

ESPR

AFP

5 months ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

ESPR

Business Insider

5 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

ESPR

Insider Monkey

5 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

ESPR

Reuters

5 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

ESPR

Insider Monkey

5 months ago

Best Date Night Fragrance in 2024

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

ESPR

Zacks

5 months ago

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

ESPR

Zacks

5 months ago

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

ESPR

Zacks

6 months ago

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion to Participate in Upcoming June Investor Conferences

ESPR

GlobeNewswire

6 months ago

Esperion to Participate in Upcoming June Investor Conferences

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

ESPR

GlobeNewswire

6 months ago

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

ESPR

MT Newswires

6 months ago

Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ESPR

GlobeNewswire

6 months ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

ESPR

GlobeNewswire

6 months ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

ESPR

GlobeNewswire

6 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR

Zacks

6 months ago

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

ESPR

Insider Monkey

6 months ago

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript

ESPR

GuruFocus.com

6 months ago

Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

ESPR

Benzinga

6 months ago

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

ESPR

GuruFocus.com

6 months ago

Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase

ESPR

MT Newswires

6 months ago

Top Premarket Gainers

ESPR

Zacks

6 months ago

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

ESPR

Associated Press Finance

6 months ago

Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Reports First Quarter 2024 Financial Results

ESPR

GlobeNewswire

6 months ago

Esperion Reports First Quarter 2024 Financial Results

Esperion to Participate in Upcoming May Investor Conferences

ESPR

GlobeNewswire

6 months ago

Esperion to Participate in Upcoming May Investor Conferences

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

ESPR

Zacks

6 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Esperion to Report First Quarter 2024 Financial Results on May 7

ESPR

GlobeNewswire

7 months ago

Esperion to Report First Quarter 2024 Financial Results on May 7

11 Best Low Price Pharma Stocks To Invest In

ESPR

Insider Monkey

7 months ago

11 Best Low Price Pharma Stocks To Invest In

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

ESPR

GlobeNewswire

7 months ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

ESPR

GlobeNewswire

7 months ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

ESPR

Zacks

7 months ago

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

ESPR

GlobeNewswire

7 months ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

ESPR

GlobeNewswire

7 months ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

ESPR

Business Wire

8 months ago

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

ESPR

GlobeNewswire

8 months ago

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

ESPR

GlobeNewswire

8 months ago

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

11 Best Small Cap Pharma Stocks to Invest In

ESPR

Insider Monkey

8 months ago

11 Best Small Cap Pharma Stocks to Invest In

ESPR

Zacks

8 months ago

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

5 Small Drug Stocks to Buy From a Rebounding Industry

ESPR

Zacks

8 months ago

5 Small Drug Stocks to Buy From a Rebounding Industry

ESPR

Insider Monkey

8 months ago

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

ESPR

Zacks

8 months ago

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

ESPR

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Esperion Therapeutics Inc Earnings Call

ESPR

GuruFocus.com

8 months ago

Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023

ESPR

Zacks

8 months ago

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

ESPR

Associated Press Finance

8 months ago

Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

ESPR

GlobeNewswire

8 months ago

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

ESPR

Insider Monkey

8 months ago

12 Best Medical Stocks to Buy Under $10

ESPR

GlobeNewswire

9 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR

Insider Monkey

9 months ago

Should You Sell Esperion Therapeutics (ESPR)?

ESPR

Zacks

9 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

ESPR

GlobeNewswire

9 months ago

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

Seadrill (SDRL) Secures New Contracts Worth $97.5 Million

ESPR

Zacks

9 months ago

Seadrill (SDRL) Secures New Contracts Worth $97.5 Million

ESPR

Business Wire

9 months ago

Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

ESPR

GlobeNewswire

9 months ago

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

Trinity Capital Receives Investment Grade Rating from Morningstar DBRS

ESPR

PR Newswire

9 months ago

Trinity Capital Receives Investment Grade Rating from Morningstar DBRS

Whether or not the Fed cuts rates is not the right question

ESPR

Yahoo Finance

9 months ago

Whether or not the Fed cuts rates is not the right question

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

ESPR

Motley Fool

9 months ago

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript

ESPR

Insider Monkey

9 months ago

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript

Q3 Earnings Outperformers: Torrid (NYSE:CURV) And The Rest Of The Apparel Retailer Stocks

ESPR

StockStory

9 months ago

Q3 Earnings Outperformers: Torrid (NYSE:CURV) And The Rest Of The Apparel Retailer Stocks

ESPR

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Old National Bancorp Earnings Call

ESPR

Associated Press Finance

10 months ago

Hanmi Financial: Q4 Earnings Snapshot

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

ESPR

GlobeNewswire

10 months ago

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

QCR Holdings (QCRH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

ESPR

Zacks

10 months ago

QCR Holdings (QCRH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Consensus Cloud Solutions to Host Q4 and 2023 Year End Investor Call on February 21, 2024

ESPR

Business Wire

10 months ago

Latest Esperion Therapeutics Inc. (ESPR) News on November 8, 2024

Share on Social Networks: